BCX Share Price Performance
zł77.60
-25.40 (-24.66%)
Price zł77.60
Share Pricen/a
We Think Bioceltix (WSE:BCX) Can Afford To Drive Business Growth
Dec 11
Bioceltix S.A. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
BCX Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Bioceltix S.A. Key Details
About BCX
- Founded
- 2016
- Employees
- 41
- CEO
- WebsiteView website
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. The company’s products include BCX-CM-J, a stem-cell based biological drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, a drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was founded in 2016 and is headquartered in Wroclaw, Poland.
